```json
{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Tau Dendritic Missorting as Gain-of-Toxic-Function Primes Neurons for Aβ-Independent Degeneration",
"mechanism": "Aβ initiates tau missorting from axons to dendrites where it disrupts NMDA receptor trafficking and spine stability, creating a self-sustaining toxic state that persists after Aβ removal.",
"target_gene": "MAPT",
"confidence_score": 0.72,
"novelty_score": 0.65,
"feasibility_score": 0.58,
"impact_score": 0.82,
"composite_score": 0.70,
"testable_prediction": "Conditional MAPT deletion after Aβ clearance in 3xTg mice will determine whether residual cognitive deficits require ongoing tau missorting maintenance.",
"skeptic_concern": "Tau missorting may be a downstream epiphenomenon rather than a causal driver of therapeutic failure; bidirectional relationship with Aβ complicates intervention timing."
},
{
"rank": 2,
"title": "Aβ-Induced Lysosomal Dysfunction Converts Tau Into Proteolysis-Resistant Seed-Competent Conformations",
"mechanism": "Aβ-mediated lysosomal permeabilization releases tau fragments that undergo conformational change into self-propagating seeds resistant to normal degradation, making them impervious to anti-Aβ approaches.",
"target_gene": "CTSD",
"confidence_score": 0.65,
"novelty_score": 0.70,
"feasibility_score": 0.52,
"impact_score": 0.78,
"composite_score": 0.68,
"testable_prediction": "Lysosomal stabilization in APP/PS1 mice via cysteamine bitartrate will test whether preventing tau conformational change abrogates seeding while anti-Aβ therapy remains effective.",
"skeptic_concern": "Distinguishing primary lysosomal dysfunction from secondary effects of existing pathology in vivo remains technically challenging."
},
{
"rank": 3,
"title": "Astrocyte Aβ Sensing Triggers Exosome-Mediated Tau Propagation That Bypasses Neuronal Aβ Dependency",
"mechanism": "Aβ-activated astrocytes release tau-laden exosomes that spread pathology to connected neurons, establishing a propagation circuit that operates independently of ongoing Aβ production.",
"target_gene": "GFAP",
"confidence_score": 0.60,
"novelty_score": 0.72,
"feasibility_score": 0.48,
"impact_score": 0.75,
"composite_score": 0.65,
"testable_prediction": "Selective astrocyte-specific Rab27a knockout in iPSC-AD models will test whether blocking exosome release prevents tau spreading when Aβ is present.",
"skeptic_concern": "Astrocyte heterogeneity and lack of human-relevant models limit translation from rodent systems."
}
],
"consensus_points": [
"Aβ-tau synergy represents a credible mechanistic framework for explaining anti-Aβ trial failures independent of trial design or patient selection issues",
"Tau-mediated gain-of-toxic-function beyond its normal axonal roles is essential for understanding the Aβ contradiction",
"The initiating event (Aβ) and maintaining drivers (tau propagation) require distinct therapeutic approaches"
],
"dissent_points": [
"Whether tau missorting is a cause or consequence of Aβ toxicity remains debated, with implications for therapeutic target validity",
"The relative contribution of neuronal versus glial mechanisms to Aβ-tau synergy is contested, with different groups emphasizing cell-type specific hypotheses"
],
"debate_summary": "The central contradiction—that Aβ targeting fails despite its presumed initiating role—resolves mechanistically through tau gaining toxic functions that become Aβ-independent once established. Three convergent hypotheses (tau missorting, lysosomal dysfunction-driven tau conformational change, and astrocyte exosome propagation) all predict that anti-Aβ monotherapy fails because tau pathology becomes self-sustaining after Aβ-induced priming. The therapeutic implication is that future trials must either target tau conversion/seeding directly or combine anti-Aβ with anti-tau approaches, with timing being critical given that earlier intervention may still prevent tau from achieving independence."
}
```